Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

Formula 82M, a minoxidil and retinol liquid, improved hair texture and filled in temples with baby hairs for the user, but its high cost and lack of reviews cause concern. Another user mentioned using a similar product, 82F, which has become less effective and expensive over time.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

A 29-year-old shared their hair recovery progress using a liposomal topical finasteride/minoxidil solution, LLLT helmet, and vitamins, noting that transplants were only on the hairline. They highlighted the effectiveness of their regimen and addressed skepticism with photos.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

A 24-year-old male has been using finasteride for 7 months and noticed thinning hair, especially when wet, and is concerned about the effectiveness of the treatment. Suggestions include continuing finasteride, considering minoxidil, and possibly trying micro-needling.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.

Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.

The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.

Mixing Pyrilutamide powder with Minoxidil solution is being considered. The Minoxidil solution contains Minoxidil 5%, Azelaic acid 5%, ABN complex 0.8%, Retinol 0.025%, Caffeine 0.001%, and a delivery vehicle.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The user is switching from oral to DIY topical finasteride due to side effects and is using a solution with 10 mg finasteride in a 100 mL mixture. They are concerned about the effectiveness of the formula due to white sediment forming in the solution.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

Topical RU58841 is discussed for hair loss treatment, with a focus on brands available in Europe that have low systemic absorption. Users suggest mixing your own solution to control vehicle and dosage, and mention different brands like Actifolic and Biolabshop.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.